CURE Pharmaceutical
1620 Beacon Place
Oxnard
California
93033
United States
Tel: 805-824-0410
Fax: 805-487-7163
Website: http://www.curepharmaceutical.com/
Email: info@curepharmaceutical.com
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada and Israel. The company's mission is to improve people's lives by redefining how medicines are delivered and experienced.
LEADERSHIP:
CEO: Robert Davidson
COO: Jessica Rousset
CFO: Alex Katz
70 articles about CURE Pharmaceutical
-
CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman
8/16/2022
CURE Pharmaceutical Holding Corp., a proprietary platform technology company, announced the appointment of former CEO Rob Davidson to Chairman of the Board of Directors.
-
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
8/9/2022
CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022.
-
CURE Pharmaceutical Announces the Appointment of New Board Member
8/2/2022
CURE Pharmaceutical Holding Corp., a proprietary platform technology company, announced the appointment of Gerald Bagg to its board of directors.
-
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary
5/12/2022
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD) CCHMC to Seek Formulary approval for CURE’s OTF Vitamin D Supplement in its Hospital Formulary OXNARD, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations
-
CURE Pharmaceutical Receives Patent Approval for Its CUREfilm Blue™ Technology
11/16/2021
CURE Pharmaceutical Holding Corp. announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021.
-
CURE Pharmaceutical Reports Second Quarter 2021 Revenue Rose Nearly 700% Driven by Sales from Sera Labs Product Lines
8/17/2021
CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced results for the quarter ended June 30, 2021.
-
CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
6/15/2021
CURE Pharmaceutical Holding Corp. announced today that its Chief Business Officer Jonathan Berlent will participate in a virtual presentation at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17.
-
CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health
6/10/2021
CURE Pharmaceutical Holding Corp. announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.
-
CURE Pharmaceutical Schedules Investor Webcast for Thursday, May 27, 2021
5/25/2021
CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time.
-
CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics
5/17/2021
CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021.
-
CURE Pharmaceutical Receives ISO Certification for Laboratory and Manufacturing Facility
5/13/2021
CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification for its Oxnard, Calif., manufacturing and research facility. ISO 9001 certification recognizes excellence in quality management standards of an organization
-
Nicole Kidman, Sera Labs Strategic Business Partner/Global Brand Ambassador and Nancy Duitch, Sera Labs Founder/CEO Headline Collision 2021 and Talk the Future of Beauty Technology
4/28/2021
Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp., headlined Collision 2021 and discussed the changing landscape of beauty, health and wellness.
-
CURE Pharmaceutical Announces Successful Results From Initial Clinical Trials for Erectile Dysfunction Product CUREfilm Blue™
4/21/2021
CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies. CURE will now advance its clinical program with the objective of U.S. Food and Drug Administration (FDA) approval.
-
CURE Pharmaceutical to Present at the 2021 Sequire Cannabis Conference on Tuesday, April 20, at 2 p.m. EDT/11 a.m. PDT
4/19/2021
CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that Rob Davidson, CURE’s Chief Executive Officer, and Nancy Duitch, CEO of subsidiary Sera Labs and Chief Strategic Officer of CURE, will be presenting virtually at a cannabis investing conference, the 2021 Sequire Cannabis Conference, on Tuesday, April 20, at 2 p.m. EDT/11 a.m. PDT.
-
Nicole Kidman, Sera Labs Strategic Business Partner/Global Brand Ambassador and Nancy Duitch, Sera Labs Founder/CEO Headline Collision 2021
4/13/2021
Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp., announced that Academy Award, Golden Globe and Emmy Award-winning actor/producer/entrepreneur Nicole Kidman and Sera Labs CEO/CURE Pharmaceutical Chief Strategic Officer, Nancy Duitch will headline Collision 2021.
-
CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020
4/1/2021
Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary The Sera Labs, Inc.
-
CURE Pharmaceutical Augments Its Existing U.S. DEA License in Order to Initiate Development of Its Psychedelics-Based Pharmaceutical Clinical Pipeline
3/23/2021
CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license that will allow the Company to conduct research on psychedelics-based pharmaceuticals
-
CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders
3/16/2021
CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, LSD, and MDMA for the treatment of various mental health disorders.
-
CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications
3/10/2021
CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline.
-
CURE Pharmaceutical’s Subsidiary Sera Labs Launches National Television, Radio & Digital Advertising Campaign for Nutri-Strips Sleep A.S.A.P.
3/3/2021
CURE Pharmaceutical Holding Corp . (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space today announced that its subsidiary Sera Labs has launched a robust national advertising campaign